Fluvastatin activates sirtuin 6 to regulate sterol regulatory element-binding proteins and AMP-activated protein kinase in HepG2 cells

Ji Hye Kim, Jun Mi Lee, Jong-Hoon Kim, Kwang Rok Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Sirtuins, a family of NAD+-dependent deacetylase enzymes, have been identified as mammalian homologs of yeast silent information regulator 2 (SIR2). Sirtuin 6 (SIRT6) plays important roles in cell homeostasis, DNA damage repair, cancer suppression, and aging. SIRT6 overexpression improves metabolic diseases, such as hypercholesterolemia, cholesterol-related disease, and type 2 diabetes via AMP-activated protein kinase (AMPK) activation. SIRT6 is abundant in the liver and is a crucial target for patients with liver steatosis. Compounds for drug repositioning were screened to identify potential SIRT6 activators, and fluvastatin, a synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase that reduces cholesterol synthesis, was identified to activate SIRT6. When HepG2 cells were treated with fluvastatin, the expression of SIRT6 and phosphorylation of sterol regulatory element-binding protein (SREBP)-1 and AMPKα which is regulated by SIRT6, increased. In this study, we examined the mechanism underlying cholesterol regulation by fluvastatin via SREBP-1 and AMPKα pathway and suggested that fluvastatin is an SIRT6 activator that regulates cholesterol homeostasis and fatty liver disease.

Original languageEnglish
Pages (from-to)1415-1421
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume503
Issue number3
DOIs
Publication statusPublished - 2018 Sep 10

Fingerprint

fluvastatin
Sterol Regulatory Element Binding Proteins
AMP-Activated Protein Kinases
Hep G2 Cells
Liver
Sterol Regulatory Element Binding Protein 1
Cholesterol
Fatty Liver
Homeostasis
Drug Repositioning
Sirtuins
Phosphorylation
Metabolic Diseases
Medical problems
Hypercholesterolemia
DNA Repair
NAD
Yeast
Type 2 Diabetes Mellitus
DNA Damage

Keywords

  • AMP-Activated protein kinaseα
  • Fluvastatin
  • Nonalcoholic fatty liver disease
  • SIRT6
  • SREBP-1

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Fluvastatin activates sirtuin 6 to regulate sterol regulatory element-binding proteins and AMP-activated protein kinase in HepG2 cells. / Kim, Ji Hye; Lee, Jun Mi; Kim, Jong-Hoon; Kim, Kwang Rok.

In: Biochemical and Biophysical Research Communications, Vol. 503, No. 3, 10.09.2018, p. 1415-1421.

Research output: Contribution to journalArticle

@article{3ff9efbb3f594dc3884776ffd14d5b64,
title = "Fluvastatin activates sirtuin 6 to regulate sterol regulatory element-binding proteins and AMP-activated protein kinase in HepG2 cells",
abstract = "Sirtuins, a family of NAD+-dependent deacetylase enzymes, have been identified as mammalian homologs of yeast silent information regulator 2 (SIR2). Sirtuin 6 (SIRT6) plays important roles in cell homeostasis, DNA damage repair, cancer suppression, and aging. SIRT6 overexpression improves metabolic diseases, such as hypercholesterolemia, cholesterol-related disease, and type 2 diabetes via AMP-activated protein kinase (AMPK) activation. SIRT6 is abundant in the liver and is a crucial target for patients with liver steatosis. Compounds for drug repositioning were screened to identify potential SIRT6 activators, and fluvastatin, a synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase that reduces cholesterol synthesis, was identified to activate SIRT6. When HepG2 cells were treated with fluvastatin, the expression of SIRT6 and phosphorylation of sterol regulatory element-binding protein (SREBP)-1 and AMPKα which is regulated by SIRT6, increased. In this study, we examined the mechanism underlying cholesterol regulation by fluvastatin via SREBP-1 and AMPKα pathway and suggested that fluvastatin is an SIRT6 activator that regulates cholesterol homeostasis and fatty liver disease.",
keywords = "AMP-Activated protein kinaseα, Fluvastatin, Nonalcoholic fatty liver disease, SIRT6, SREBP-1",
author = "Kim, {Ji Hye} and Lee, {Jun Mi} and Jong-Hoon Kim and Kim, {Kwang Rok}",
year = "2018",
month = "9",
day = "10",
doi = "10.1016/j.bbrc.2018.07.057",
language = "English",
volume = "503",
pages = "1415--1421",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Fluvastatin activates sirtuin 6 to regulate sterol regulatory element-binding proteins and AMP-activated protein kinase in HepG2 cells

AU - Kim, Ji Hye

AU - Lee, Jun Mi

AU - Kim, Jong-Hoon

AU - Kim, Kwang Rok

PY - 2018/9/10

Y1 - 2018/9/10

N2 - Sirtuins, a family of NAD+-dependent deacetylase enzymes, have been identified as mammalian homologs of yeast silent information regulator 2 (SIR2). Sirtuin 6 (SIRT6) plays important roles in cell homeostasis, DNA damage repair, cancer suppression, and aging. SIRT6 overexpression improves metabolic diseases, such as hypercholesterolemia, cholesterol-related disease, and type 2 diabetes via AMP-activated protein kinase (AMPK) activation. SIRT6 is abundant in the liver and is a crucial target for patients with liver steatosis. Compounds for drug repositioning were screened to identify potential SIRT6 activators, and fluvastatin, a synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase that reduces cholesterol synthesis, was identified to activate SIRT6. When HepG2 cells were treated with fluvastatin, the expression of SIRT6 and phosphorylation of sterol regulatory element-binding protein (SREBP)-1 and AMPKα which is regulated by SIRT6, increased. In this study, we examined the mechanism underlying cholesterol regulation by fluvastatin via SREBP-1 and AMPKα pathway and suggested that fluvastatin is an SIRT6 activator that regulates cholesterol homeostasis and fatty liver disease.

AB - Sirtuins, a family of NAD+-dependent deacetylase enzymes, have been identified as mammalian homologs of yeast silent information regulator 2 (SIR2). Sirtuin 6 (SIRT6) plays important roles in cell homeostasis, DNA damage repair, cancer suppression, and aging. SIRT6 overexpression improves metabolic diseases, such as hypercholesterolemia, cholesterol-related disease, and type 2 diabetes via AMP-activated protein kinase (AMPK) activation. SIRT6 is abundant in the liver and is a crucial target for patients with liver steatosis. Compounds for drug repositioning were screened to identify potential SIRT6 activators, and fluvastatin, a synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase that reduces cholesterol synthesis, was identified to activate SIRT6. When HepG2 cells were treated with fluvastatin, the expression of SIRT6 and phosphorylation of sterol regulatory element-binding protein (SREBP)-1 and AMPKα which is regulated by SIRT6, increased. In this study, we examined the mechanism underlying cholesterol regulation by fluvastatin via SREBP-1 and AMPKα pathway and suggested that fluvastatin is an SIRT6 activator that regulates cholesterol homeostasis and fatty liver disease.

KW - AMP-Activated protein kinaseα

KW - Fluvastatin

KW - Nonalcoholic fatty liver disease

KW - SIRT6

KW - SREBP-1

UR - http://www.scopus.com/inward/record.url?scp=85050851678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050851678&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2018.07.057

DO - 10.1016/j.bbrc.2018.07.057

M3 - Article

C2 - 30078674

AN - SCOPUS:85050851678

VL - 503

SP - 1415

EP - 1421

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -